Tests a targeted radiation method in adults with returning glioblastoma
Tests radiation guided by a PET scan in adults with recurrent glioblastoma brain tumors.
Plain-language title generated from the registry record
Registry title: Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
Key facts
- Where
- Nancy and Strasbourg, FranceSee the 2 sites
- Phase
- Phase 2
Where in France
- CHRU de NancyNancy, FranceNot yet recruiting
- Centre Paul StraussStrasbourg, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Paul Strauss
- Trial code
- NCT05653635
- Record updated
- 4 February 2026
- Original description
ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.Read full original descriptionShow less
Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.
Inclusion: Age > 18 years; Glioblastoma, World Health Organization (WHO) grade IV, histologically proven; Performance status 0, 1 or 2; Neurological status ≥ 2; Past irradiation in previsional re-irradiated site or in the vicinity (5 to 7 cm); Radiological proven recurrence according to 1 and 2 criteria, Wen et al; Remaining node after partial surgery post-recurrence; 1 to 3 recurrence site(s) < 35 mm in wide axis and separated by at least 5 mm; Volume of each lesion < 35 mL; Distance between recurrence node(s) and optic nerves (left and right), chiasma and/or cerebral trunk > 10 mm.
Exclusion: Patient with contraindication to MRI or PET; Glioblastomatose; Pregnancy or breastfeeding; Patient that do not understand French; Patient without affiliation to the national or local social security; Patients not able to comply to the protocol assessments for geographic, social or psychological reasons; Minor or patients placed under guardianship or supervision; Patients deprived of liberty; Patients placed under judicial protection; Patients that are not able to express their consent.